Circulating exosomal long noncoding RNA PRINS-First findings in monoclonal gammopathies
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu klinické zkoušky, časopisecké články
Grantová podpora
AZV 15-29508A
Czech Ministry of Health
PubMed
30144133
PubMed Central
PMC6585732
DOI
10.1002/hon.2554
Knihovny.cz E-zdroje
- Klíčová slova
- biomarker, long noncoding RNA, monoclonal gammopathy of undetermined significance, multiple myeloma, qPCR,
- MeSH
- dospělí MeSH
- exozómy metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- mnohočetný myelom * krev diagnóza mortalita MeSH
- přežití bez známek nemoci MeSH
- RNA dlouhá nekódující krev MeSH
- RNA nádorová krev MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- Názvy látek
- RNA dlouhá nekódující MeSH
- RNA nádorová MeSH
Multiple myeloma is the second most common hematological malignancy characterized by focal lesions of malignant plasma cells in the bone marrow. These lesions contain subclones that directly influence survival of patients. Bone marrow biopsies are single-site biopsies and thus cannot contain all information about the tumor. In contrast, liquid biopsies analyze circulating cells and molecules that are secreted from all sites of the tumor. Long noncoding RNA molecules are one class of these molecules. We performed a two-phase biomarker study investigating lncRNA expression profiles in exosomes of peripheral blood serum of newly diagnosed multiple myeloma (MM) patients, monoclonal gammopathy of undetermined significance (MGUS) patients in comparison with healthy donors (HD). Surprisingly, this analysis revealed dysregulation of only one exosomal lncRNA PRINS in MM vs HD. Overall, MM and MGUS patients were distinguished from HD with sensitivity of 84.9% and specificity of 83.3%. Our study suggests a possible diagnostic role for exosomal lncRNA PRINS in monoclonal gammopathies patients.
Central European Institute of Technology Masaryk University Brno Czech Republic
Department of Clinical Hematology University Hospital Brno Brno Czech Republic
Department of Experimental Biology Faculty of Science Masaryk University Brno Czech Republic
Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
Zobrazit více v PubMed
Rajkumar VS. MDUpdated diagnostic criteria and staging system for multiple myeloma. J Clin Oncol. http://meetinglibrary.asco.org/content/159009‐176 (accessed 4 March 2017 PubMed
Hocking J, Mithraprabhu S, Kalff A, Spencer A. Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies. Cancer Biol Med. 2016;13(2):215‐225. PubMed PMC
Kubaczkova V, Vrabel D, Sedlarikova L, Besse L, Sevcikova S. Cell‐free DNA—minimally invasive marker of hematological malignancies. Eur J Haematol. 2017;99(4):291‐299. PubMed
Kubiczkova L, Kryukov F, Slaby O, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 2014;99(3):511‐518. PubMed PMC
Besse L, Sedlarikova L, Kryukov F, et al. Circulating serum MicroRNA‐130a as a novel putative marker of extramedullary myeloma. PLoS One. 2015;10(9):e0137294. PubMed PMC
Manier S, Liu C‐J, Avet‐Loiseau H, et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. Epub ahead of print 17 February. 2017;129(17):2429‐2436. 10.1182/blood-2016-09-742296 PubMed DOI PMC
Isin M, Ozgur E, Cetin G, et al. Investigation of circulating lncRNAs in B‐cell neoplasms. Clin Chim Acta Int J Clin Chem. 2014;431:255‐259. PubMed
Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775‐1789. PubMed PMC
Zhang Q, Su M, Lu G, Wang J. The complexity of bladder cancer: long noncoding RNAs are on the stage. Mol Cancer. 2013;12(1):101. PubMed PMC
Sedlarikova L, Gromesova B, Kubaczkova V, et al. Deregulated expression of long non‐coding RNA UCA1 in multiple myeloma. Eur J Haematol. 2017;99(3):223‐233. PubMed
Nemec P, Zemanova Z, Kuglik P, et al. Complex karyotype and translocation t(4;14) define patients with high‐risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk Lymphoma. 2012;53(5):920‐927. PubMed
Sonkoly E, Bata‐Csorgo Z, Pivarcsi A, et al. Identification and characterization of a novel, psoriasis susceptibility‐related noncoding RNA gene, PRINS. J Biol Chem. 2005;280(25):24159‐24167. PubMed
Szegedi K, Sonkoly E, Nagy N, et al. The anti‐apoptotic protein G1P3 is overexpressed in psoriasis and regulated by the non‐coding RNA, PRINS. Exp Dermatol. 2010;19(3):269‐278. PubMed
Bari L, Bacsa S, Sonkoly E, et al. Comparison of stress‐induced PRINS gene expression in normal human keratinocytes and HaCaT cells. Arch Dermatol Res. 2011;303(10):745‐752. PubMed
Glover AR, Zhao JT, Ip JC, et al. Long noncoding RNA profiles of adrenocortical cancer can be used to predict recurrence. Endocr Relat Cancer. 2015;22(1):99‐109. PubMed
Shen X, Zhang Y, Wu X, et al. Upregulated lncRNA‐PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum. Cancer Biomark Sect Dis Markers. 2017;18(3):257‐263. PubMed
Pan Y, Chen H, Shen X, et al. Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma. Clin Chim Acta. 2018. May;480:199‐205. PubMed
